Kornimate/medical-research-clean huggingface dataset:
reconstructions with back donor site flaps and validation of quality of life scales

Conditions: Breast Cancer

Summary: the latissimus dorsi flap is the oldest and most used technique for breast reconstruction. nonetheless, there are few studies evaluation the long-term effect of harvesting one of the muscles of the back. this project has four parts. 1. validation of scales/instrument for swedish. 2. long-term results after reconstruction with latissimus dorsi- a ten year retrospective follow-up. 3. thoracodorsal artery perforator flap (tdap) vs latissimus dorsi flap- a randomized controlled trial - breast reconstruction. 4. tdap vs limber flap - a randomized controlled trial- reconstruction of axillary hidradenitis suppurativa.


Eligibility criteria:
inclusion criteria: * patients eligible for breast reconstruction following mastectomy and radiation * non-smokers or ex-smokers (\>6 weeks) * bmi \< 30 exclusion criteria: * inability to leave informed consent * inability to understand swedish * previous surgery with scaring on back
assessment of bronchial asthma among patients attending sohag university hospital

Conditions: Bronchial Asthma

Summary: asthma is a significant public health threat, affecting more than 300 million individuals globally. asthma is classified as a non-communicable disease and leads to reduced quality of life, poor physical functioning and reduced emotional well-being. the impact of this disease can be widespread and extends beyond the person living with the disease, affecting the lives of their family members, carers, communities and the health care system (1). asthma is a variable chronic respiratory condition. it is characterized by symptoms of wheeze, cough, chest tightness, dyspnea and backed by variable airflow limitation, airway inflammation and airway hyper-responsiveness (ahr). the severity of asthma varies considerably, both between individuals and within individuals over time. some people may have intermittent asthma and others may experience severe, potentially life-threatening disease (2, 3,4).


Eligibility criteria:
inclusion criteria: * bronchial asthma patients aged more than 18 years, both sexes are included exclusion criteria: * children ,patients who are unable to do spiromerty or contrindecated
ghrelin with anorexia nervosa

Conditions: Anorexia Nervosa

Summary: the picowo research group in corporation with the university of amsterdam (artificial intelligence) has developed a computer simulationmodel of eating disorders (bosse, delfos, jonker \& treur, 2003). in a running phd project we want to add ghrelin to the model. the idea for this current research is to collect clinical information about the functioning and (patho)physiology of ghrelin in patients with an, so we can extend the simulation.

eating disorders are in need of new perspectives. a better understanding of the appetite in patients with eating disorders, especially anorexia nervosa, could be investigated by the levels of ghrelin in patients with and without tube feeding.

Eligibility criteria:
inclusion criteria: * studypopulation: patiënts: all female, non -age coupled. * subgroup patients without tube feeding, with tube feeding and a healthy matched control group. * control group: healty volunteers of the university of maastricht. exclusion criteria: * patients with a history of eating disorder different than an or a psychiatric history. * control group: no history of eating disorders or other psychiatric disabilities. normal physical examination, ecg, laboratorium (blood cells, liver, kidneys)

Keywords: anorexia nervosa
special drug use investigation for amerge® tablet (long-term)

Conditions: Migraine Disorders

Summary: to investigate the long-term safety and efficacy of amerge (naratriptan hydrochloride) on japanese patients with migraine headache in clinical setting


Eligibility criteria:
inclusion criteria: * must use amerge for the first time exclusion criteria: * patients with hypersensitivity to naratriptan or any of the components. * patients with history, symptoms, or signs of myocardial infarction, ischemic cardiac or angina inversa * patients with history of cerebral vascular disturbance or transient ischaemic attack * patients with peripheral vascular syndromes * patients with uncontrolled hypertension * patients with severe renal or hepatic impairment * patients using treatment with another 5-ht1 agonist, an ergotamine-containing or ergot-type medication
aerobic exercise for women with fibromyalgia

Conditions: Fibromyalgia

Summary: this is randomized controlled trial that investigated the effect of aerobic exercises in women with fibromyalgia. the study was performed in abu-kabir central hospital - al sharquia, egypt. the sample was recruited from the rheumatology department in abu-kabir central hospital- al sharquia. sixty women were included in the study based on the inclusion criteria. the first group (study group) included 30 participants who received aerobic exercise in addition to the prescribed medications. the second group (control group) included 30 participants who received the prescribed medications only. the outcome measures included visual analogue scale, fibromyalgia impact questionnaire and cholesterol level. assessment of outcomes were performed at baseline and after the end of treatment program.


Eligibility criteria:
inclusion criteria: * (1)their ages ranged from 30 to 40 years old (2)their body mass index (bmi) was from 20:26 kg/m2 (3)all patients assured diagnosis fibromyalgia for more than three months (4)participants were on a stable regimen of pharmacological and/or non pharmacological treatment for fm the previous three months leading up to study period and agree to maintain their present medication unchanged for the duration of their participation in the study exclusion criteria: patients with pregnancy, another accompanying central sensitization syndrome patients with psychiatric illness patients whose pharmacological treatment for fms changed within the last three months patients who do not have a cognitive level to answer the questions in the scale
measuring hydration levels of healthy and heart failure patients before, during, and after an electrophysiology (ep) procedure

Conditions: Cardiac Arrhythmia

Summary: subjects will be consented to wear the aleritm sensor prior to, during, and after an electrophysiology procedure. during this time, the system will measure the following parameters from subjects: hr, temperature, saline volume/rate, urine production volume, usg, bpo. data will be retrospectively analyzed to determine if the system effectively operates under these conditions, and can effectively monitor hydration levels of subjects compared to currently available methods.

study subjects scheduled for an ep procedure who have signed an informed consent form (icf) will be admitted to the study. prior to the ep procedure (e.g. in a hospital room or operating room at nyu medical center), either an employee of nyu or hydrostasis will place sensor on subject's bicep, forearm, or wrist, start the sensor and connect the sensor to mobile app to start data collection.

Eligibility criteria:
inclusion criteria: * patients with cardiac arrhythmias or other cardiac conditions that are scheduled for ep procedures. * subject is over 18 years of age at the time of consenting * subject and/or legally authorized representative is willing to undergo the informed consent process prior to enrollment in the study exclusion criteria: * pregnant subjects * subjects who are participating in another clinical study that may affect the results of either study * subjects who are unwilling or unable to wear the sensor for a period of up to 14 hours * subjects who are considered by the principle investigator to be medically unsuitable for study participation
a clinical study of tqc2731 injection in patients with moderate to severe chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: to evaluate the efficacy and safety of tqc2731 injection in patients with moderate to severe chronic obstructive pulmonary disease.


Eligibility criteria:
inclusion criteria: * able and willing to provide written informed consent and comply with the study protocol; * participant must be ≥40 to ≤80 years of age at the time of signing informed consent. * participants with a physician diagnosis of chronic obstructive pulmonary disease(copd) and a history of copd ≥12 months with medical records or related records at the time of screening; * post-bronchodilator fev1/forced vital capacity (fvc)\<0.70 and post-bronchodilator fev1 % predicted ≥20% and \< 80% during screening. * modified medical research council (mmrc) dyspnea scale grade≥2 during screening. * background triple therapy (ics+long-acting beta-agonists (laba)+lama) for at least 3 months with a stable dose for at least 1 month prior to randomization; double therapy allowed if ics is contraindicated. * with a history of acute exacerbation of ≥2 moderate or ≥1 severe within the previous 12 months prior to screening. exclusion criteria: * copd with asthma; * subjects with active pulmonary diseases other than copd assessed by the investigator. * moderate to severe acute exacerbations of chronic obstructive pulmonary disease (aecopd) occurred within 4 weeks prior to screening or during screening; * history of lung transplantation; * previous use of tqc2731. * diagnosis of alpha-1 anti-trypsin deficiency; * history of lung volume reduction surgery or pneumonectomy within 6 months prior to randomization, or planned lung volume reduction surgery during the study period; * positive hepatitis b surface antigen, or hepatitis c virus antibody, or syphilis antibody. * diagnosis of immunodeficiency, including but not limited to hiv infection; * infection requiring systemic therapy within 2 weeks prior to randomization. * starting rehabilitation within 4 weeks prior to randomization, or planned rehabilitation during the study period; * treatment with oxygen of more than 12 hours per day. * heart failure new york heart association (nyha) class iii or iv during the screening period. * history of malignancy within 5 years prior to screening, excluding cervical carcinoma in situ, ductal carcinoma in situ, etc. * pregnancy or breastfeeding.
evaluation of an early screener to identify long-term problems with regard to metabolic control and treatment adherence among children and adolescents with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: background: type 1 diabetes is one of the most common chronic illnesses among children and adolescents. although, intensive medical care is provided for these patients, some of them have poor metabolic control. for example, only 21% of adolescents with type 1 diabetes in the usa achieve the recommended average blood sugar concentration (hba1c\<7.5%). this is a major problem, since chronic hyperglycemia is the primary cause of morbidity and mortality in type 1 diabetes and causes several serious complications, for example kidney failure, blindness, and stroke. therefore, the international society for pediatric and adolescent diabetes (ispad) declared psychosocial factors, to be the most important risk factors of poor type 1 diabetes management. therefore, an instrument is needed to identify children and adolescents with poor metabolic control in their course of disease as soon as possible. with an early identification of such risk patients, better support can be provided. however, there is no such instrument yet for pediatric patients with type 1 diabetes. to fill this gap, a questionnaire (fepb) based on the pat 2.0© (psychosocial assessment tool; an instrument used in oncology) was developed for this project. aim: the aim of this project is to evaluate and validate a new instrument (fepb) for an early identification of children and adolescents with poor metabolic control in their course of disease in a longitudinal design. method: the sample consists of children and adolescents (age: 5-18 years), who were newly diagnosed with type 1 diabetes (2-4 weeks ago), and who are in care at the university children's hospital of zurich. structured interviews are conducted with the patients and the parents are asked to fill out some questionnaires at two times: first, 2-4 weeks after the diagnosis (t1) and second 6 month later (t2). with the new instrument (fepb) a risk score can be calculated for each patient at t1. statistical analysis will be performed to determine whether that risk score can predict which patients have poor metabolic control (hba1c \> 7.5%) at t2.


Eligibility criteria:
inclusion criteria: * diagnosed with type 1 diabetes 2-4 weeks ago * in care at the university children's hospital of zurich * german speaking exclusion criteria: * other severe illness that affects the diabetes management * severe developmental disorder * pregnancy

Keywords: type 1 diabetes metabolic control psychosocial risk factors fepb children adolescents
correlation analysis of pod and pncd in elderly spinal surgery patients

Conditions: Postoperative Delirium; Postoperative Neurocognitive Disorder; Spinal Surgery

Summary: this study is a prospective cohort study to investigate the differences in serum indexes between elderly spinal surgery patients with postoperative delirium (pod) who either develop or do not develop long-term postoperative neurocognitive disorders (pncd).

to investigate the differences in serum indexes between elderly spinal surgery patients with postoperative delirium (pod) who either develop or do not develop long-term postoperative neurocognitive disorders (pncd). neurocognitive function of the study participants was assessed within one week before surgery using the montreal cognitive assessment (moca). compare changes in serum indexes level before and after surgery. under routine anesthetic management of the department of anesthesiology and surgical operations at xuanwu hospital, endotracheal intubation general anesthesia was performed. within 7 days post-surgery, delirium assessment was conducted using the confusion assessment method (cam), classifying patients into pod and non-pod groups. neurocognitive function assessments were conducted long-term after surgery for the pod group to determine the presence of pncd, further dividing the pod group into pncd and non-pncd subgroups, followed by serum indexes.by comparing the changes of serum indexes before and after surgery between the pncd and non-pncd subgroups, exploring the correlation of pod and pncd.

Eligibility criteria:
inclusion criteria: * patients ≥65 years of age who have undergone spinal surgery anesthesia; sign informed consent exclusion criteria: * inability to complete cognitive function assessment; illiteracy, hearing impairment or visual impairment; he has a history of epilepsy, depression, schizophrenia, alzheimer's disease and other psychiatric and neurological diseases

Keywords: postoperative delirium postoperative neurocognitive disorder serum indexes spinal surgery
a simulation training program for person-centered in-home dementia care

Conditions: Dementia

Summary: this study primarily explores the impact of a person-centered dementia home care scenario-based training program on home care workers' empathy, care preparedness, competence, predictability, and rewards.


Eligibility criteria:
inclusion criteria: (a) aged 20 years or older; (b) employed as a full-time worker in a home-based long-term care service institution; (c) willing to participate in this study. exclusion criteria: * employed as a part-time worker in a home-based long-term care service institution
reducing sedentary behaviors among colorectal cancer survivors

Conditions: Colorectal Cancer

Summary: interview colorectal cancer survivors and use this input to create a brochure intended to guide reduction of sedentary behaviors in this population. have colorectal cancer survivors review and comment on a draft of the brochure. a third group of colorectal cancer survivors will wear an actigraph activity monitor for one week, then receive feedback on their activity level with the brochure. after one month this group will be surveyed by telephone regarding their use of the brochure, and their physical activity level.


Eligibility criteria:
inclusion criteria: * adult * early (stage 1 or 2) colorectal cancer * 6 months or greater post treatment * does not follow guidelines for physical activity * average at least 6 hours a day of sedentary behaviors exclusion criteria: -

Keywords: colorectal cancer survivor exercise physical activity sedentary
the effect of norepinephrine and dopamine on radial forearm free flap tissue oxygen pressure and microdialysate metabolite measurements

Conditions: Head and Neck Cancer

Summary: vasopressors may be needed after head and neck microvascular reconstructions to maintain sufficient mean arterial pressure. this is crucial for the flap survival. the study hypothesis is that norepinephrine and dopamine used as vasopressors do not affect flap tissue oxygen level and microdialysate metabolites.


Eligibility criteria:
inclusion criteria: * head and neck cancer patients having tumor ablation surgery and reconstruction with microvascular radial forearm flap exclusion criteria: * patients having contraindications for the operation. * patient refusal to participate in the study
a study of flovent in patients with eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: the purpose of this study is to test the effects (both good and bad) of high dose swallowed fluticasone propionate (flovent) in subjects with eosinophilic esophagitis (eoe).


Eligibility criteria:
inclusion criteria: * signed informed consent for study by subject, or parent/guardian if subject is a minor. assent will be obtained from all minors 11 years of age and older. * histological findings on esophageal biopsy to include peak eosinophil density ≥ 24 per high power field (400x) in the proximal or distal esophagus validated by a pathologist at cchmc. * allergy evaluation including skin-prick testing with multiple food antigens to ensure elimination diet is not indicated. * have undergone a minimum 3 months of elimination diet as indicated by skin-prick testing without detectable resolution by repeat endoscopy with biopsies demonstrating persistent ee or subject/parental refusal to follow elimination diet. if the subject/parent refuses the elimination diet, they are eligible for this study. * treatment with a proton-pump inhibitor for at least two months (rounded to nearest month) prior to endoscopy or failure of histological improvement as defined by \< 1 eosinophil per hpf after 2 month (rounded to nearest month) trial of proton pump inhibitor documented by prior endoscopy. the ppi must be used prior to endoscopy to rule out the possibility of gerd. exclusion criteria: * history of poor tolerance to fluticasone propionate (fp), as defined as multiple episodes of oral candidiasis, hypothalamic-pituitary-adrenal axis suppression as evidenced by signs of cushing syndrome, headaches, or increased respiratory infections during exposure to flovent * unable to cooperate with use of mdi * pregnant females * concurrent or recent (within 3 months) use of systemic corticosteroids. * unable to swallow medicines (i.e., fed only by gastrostomy tube). * comorbid eosinophilic disorders. * previously treated with swallowed glucocorticoid for ee within 3 months of the screening visit. nasal glucocorticoids taken for ee are permitted.

Keywords: eosinophilic esophagitis
mucoid staphylococcus aureus in cystic fibrosis airways

Conditions: Staphylococcus Aureus Pneumonia; Lung Diseases; Cystic Fibrosis; Lung Function Decreased

Summary: recently, the investigators described a new mucoid phenotype of staphylococcus aureus cultured from the airways of cystic fibrosis (cf) patients.in this observational study, the investigators plan to determine the prevalence of mucoid s. aureus in respiratory specimens of cf patients and a possible impact of mucoid s. aureus on lung disease severity.

s. aureus is one of the first isolated pathogens recovered from the airways of cf patients. in many patients, s. aureus persists for decades in spite of antibiotic treatment and host defence. during persistence in the airways, s. aureus needs to adapt to this hostile niche. just recently, the investigators described mucoid s. aureus isolates as a so far not reported phenotype recovered from the airways of cf patients. these mucoid isolates carried a 5bp-deletion in a part of the "intercellular adhesion operon (ica) leading to hyper-expression of biofilm. so far, neither the prevalence of mucoid s. aureus nor the impact on lung disease in cf patients is known. the investigators plan to perform a clinical study to determine the prevalence of mucoid s. aureus isolates in a cross-sectional study and the impact of identified mucoid s. aureus on the clinical course of the lung disease by observing patients with mucoid s. aureus for 12 months in comparison with a group of age-, gender- and p. aeruginosa-positive/negative matched group of s. aureus-positive patients without mucoid isolates.

Eligibility criteria:
inclusion criteria: * cf patients with chronic s. aureus in respiratory specimens (50% positive s. aureus cultures within one or two years before recruitment) exclusion criteria: * none

Keywords: cystic fibrosis staphylococcus aureus mucoid
small airways disease in asymptomatic and symptomatic subjects with airway hyperresponsiveness (ahr)

Conditions: Asthma; Airway Hyperresponsiveness

Summary: the purpose of this study is to study differences in small airways (\<2mm) parameters in asthma patients, subjects with asymptomatic airway hyperresponsiveness and healthy controls.


Eligibility criteria:
inclusion criteria for asymptomatic subjects with airway hyperresponsiveness (ahr) : * age between 18 and 65 years. * forced expiratory volume in one second (fev1) \> 80% predicted post bronchodilator. * provocative concentration causing a 205 fall in fev1 (pc20) methacholine \<8 mg/ml. * no history of asthma or previous use of asthma medication. inclusion criteria for asymptomatic subjects without ahr : * age between 18 and 65 years. * fev1 \> 80% predicted post bronchodilator. * pc20 methacholine \>8 mg/ml. * no history of asthma or previous use of asthma medication. inclusion criteria for patients with asthma: * age between 18 and 65 years. * fev1 \> 80% predicted. * pc20 methacholine ≤8 mg/ml. * doctor's diagnosis of asthma. * no history of chronic obstructive pulmonary disease (copd). exclusion criteria: * use of inhaled or oral steroids, antihistamines, nedocromil, theophylline, leukotrien antagonists or long-acting beta-agonists for at least three weeks before the start of the study. * any disease that may affect the outcome of the study as judged by the investigator. * fev1 \<1.2 liter.

Keywords: asthma airway hyperresponsiveness asymptomatic airway hyperresponsiveness small airways